BIIL 284 BS, high dose
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Boehringer Ingelheim
Overview
BIIL 284 BS, high dose is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
BIIL 284 BS, high dose clinical trials
Explore related
Medical disclaimer. This page summarizes research about BIIL 284 BS, high dose for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.